Emergent BioSolutions Inc.
For the period ended Aug 5, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 5, 2026 · Filed Aug 5, 2026
Use the contents to explore the available documents and sections.
EBS$6.06+3.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in millions, except per share data)
(in millions, except per share data)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $139.7 | $205.4 |
| Restricted cash | 1.2 | 3.7 |
| Accounts receivable, net | 190.0 | 84.2 |
| Inventories, net | 303.6 | 343.4 |
| Prepaid expenses and other current assets | 25.4 | 25.8 |
| Assets held-for-sale | 6.1 | — |
| Total current assets | 666.0 | 662.5 |
| Property, plant and equipment, net | 178.0 | 205.4 |
| Intangible assets, net | 261.8 | 436.5 |
| Other assets | 11.0 | 14.2 |
| Total assets | $1,116.8 | $1,318.6 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $50.2 | $55.6 |
| Accrued expenses | 17.1 | 12.2 |
| Accrued compensation | 26.2 | 41.8 |
| Deferred revenue | 15.0 | 5.0 |
| Current tax liability | 4.4 | 6.8 |
| Other current liabilities | 9.9 | 10.8 |
| Total current liabilities | 122.8 | 132.2 |
| Debt | 581.8 | 572.1 |
| Deferred tax liability | 35.4 | 37.8 |
| Other liabilities | 35.4 | 53.9 |
| Total liabilities | $775.4 | $796.0 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued and outstanding | — | — |
| Common stock, $0.001 par value per share; 200.0 shares authorized, 61.9 and 60.9 shares issued; 51.3 and 52.1 shares outstanding, respectively. | 0.1 | 0.1 |
| Treasury stock, at cost, 10.7 and 8.7 common shares, respectively | (270.5) | (252.6) |
| Additional paid-in capital | 951.8 | 942.4 |
| Accumulated other comprehensive loss, net | (6.8) | (7.5) |
| Accumulated deficit | (333.2) | (159.8) |
| Total stockholders’ equity | $341.4 | $522.6 |
| Total liabilities and stockholders’ equity | $1,116.8 | $1,318.6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.